Bavituximab: Additional Phase II data

Additional data from an open-label, international Phase II trial in 83 evaluable patients with previously untreated stage IIIb/IV NSCLC showed that once-weekly 3 mg/kg bavituximab plus carboplatin and paclitaxel led an estimated median PFS of 5.8 months vs. 4.6 months for carboplatin and paclitaxel alone. Bavituximab plus chemotherapy led to an ORR of 32% vs. 31% for chemotherapy alone. Additionally, an independent central imaging review showed that bavituximab plus chemotherapy led to an estimated median PFS of 6.7 months and an ORR of 25% vs. 6.4 months and 23%, respectively, for chemotherapy alone. The company plans to report median OS data next half. ...